Voluntis
Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.
- Company typePrivate
- Founded2001
- HeadquartersSuresnes, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Voluntis does
Voluntis is a France-based, public digital health company (EPA: ALVTX) founded in 2001 and now operating as Aptar Digital Health, a division of Aptar Pharma. The company builds a certified, cloud-native digital health platform that delivers companion apps, connected drug-delivery devices, Software as a Medical Device (SaMD), digital Patient Support Programs, and Study & Data Services to global pharmaceutical and biotech partners across 120 countries. Its portfolio includes proprietary consumer-facing apps (Migraine Buddy, Esme for multiple sclerosis, Allergy Buddy), connected drug-delivery hardware such as the FDA 510(k)-cleared HeroTracker Sense, and AI-powered screening algorithms licensed to AstraZeneca.
The platform is underpinned by ISO 13485, ISO 27001, MDSAP, HIPAA, and GDPR certifications and is designed for integration with EHRs, sensors, hubs, and patient support workflows. Voluntis monetizes through multi-year enterprise SaaS subscriptions with pharma and biotech partners, connected device sales, IP licensing (e.g., AstraZeneca AI screening algorithms), and professional services for virtual clinical studies and real-world evidence generation. Its named enterprise customers include AbbVie, Bristol Myers Squibb, Chiesi, Eisai, Novartis, Sanofi, AstraZeneca, and Stallergenes Greer, with partnerships extending to medical device manufacturers (Enable Injections), consumer health products (Oura), and healthcare providers (Moffitt Cancer Center).
The business model is enterprise B2B sales-led, with co-developed and tailored solutions per pharma partner, supported by channel partnerships and event-driven demand generation at conferences such as CMSC and HLTH Europe. With 51–100 employees and operations spanning 120 countries, 17 clinical studies supported, and 15+ regulatory approvals, Voluntis operates as a focused mid-sized regulated digital health unit leveraging Aptar Pharma's global drug-delivery infrastructure.
Voluntis firmographics
Firmographics- Name
- Voluntis
- Legal name
- Voluntis
- Website
- https://voluntis.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.
- Ownership category
- akta.pro rank
Voluntis industry classification
Industry- Product category
- Digital Health Software
- NAICS
- Software Publishers (51321)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
- akta.pro secondary industries
- Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)
Keywords
Where Voluntis is headquartered
LocationHeadquarters
- HQ city
- Suresnes
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Voluntis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- B2B Enterprise SaaS for Pharma: Subscription/contract-based revenue from pharmaceutical and biotech partners licensing the digital health platform, companion apps, connected devices, and SaMD solutions. Long-term enterprise contracts with global life sciences partners.
- Connected Drug-Delivery Device Sales: Revenue from connected drug-delivery device solutions (e.g., HeroTracker Sense) integrated with patient companion apps to capture usage and adherence data.
- Licensing Agreements: Licensing revenue from agreements such as the AstraZeneca deal to develop AI-Powered Screening Algorithms, monetizing proprietary technology through IP licensing.
- Study & Data / Real-World Evidence Services: Professional services revenue from running virtual clinical studies, post-marketing studies, and generating real-world evidence for pharma brand teams using digital capabilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Tailored enterprise offers based on digital health project requirements |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Voluntis product offering
Product offeringCore offering
Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.
Product overview
Aptar Digital Health — the division of Aptar Pharma that houses Voluntis — operates as a platform-plus-modules architecture delivered to global pharma and biotech partners across 120 countries. The certified, cloud-native platform underpins a portfolio of regulated companion apps (including Migraine Buddy®, Esme, and Allergy Buddy), connected drug-delivery devices (such as the FDA 510(k)-cleared HeroTracker® Sense), Software as a Medical Device (SaMD) modules, Digital PSPs, a Disease Management Platform, and Study & Data Services. The named apps (Migraine Buddy, Esme, Allergy Buddy) and HeroTracker® Sense are concrete user- or patient-facing offerings built on top of the core platform, while SaMD, Digital PSP, Disease Management Platform, and Study Support are configurable modules/engagement models used to tailor solutions to specific drugs, indications, and patient journeys.
Differentiator
Problem solved
Functional benefit
Products and services
- HeroTracker Sense
Quantifiable outcome
- Operates across 120 countries globally
- +3 more outcomes
Companies that use Voluntis
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Voluntis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature8 records
Voluntis partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and flagship.
- Enable InjectionscorePartnership to develop the enFuse® Companion Digital Solution, combining Enable Injections' enFuse wearable drug-delivery platform with Aptar Digital Health's digital health expertise to enhance patient experience during self-administration. Announced April 9, 2026.
- ŌURAcoreCollaboration to advance migraine insights by connecting Migraine Buddy® with the Oura Ring, enabling users to correlate physiological data with migraine symptoms, triggers, and treatments. Announced January 7, 2026.
- AstraZenecaflagshipLicensing agreement to develop AI-Powered Screening Algorithms, leveraging Aptar Digital Health's AI capabilities under license for AstraZeneca's therapeutic areas. Announced May 22, 2025.
- Aptar PharmaflagshipOperates as "A Division of Aptar Pharma", benefiting from parent company's drug delivery expertise, global pharma relationships, and operational scale.
- AbbViecoreGlobal pharmaceutical partner leveraging the digital health platform; listed among "trusted partner of leading pharmaceutical companies at a global level".
- Bristol Myers SquibbcoreGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
- ChiesicoreGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
- EisaicoreGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
- NovartisflagshipGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner of leading pharmaceutical companies at a global level.
- SanofiflagshipGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
- Stallergenes GreercorePharmaceutical partner in respiratory/allergy therapeutic area leveraging the digital health platform.
- Moffitt Cancer CentercoreHealthcare/cancer center partner supporting oncology-related digital health initiatives; logo featured on the website partner wall.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Voluntis competitors and assessment
Company assessmentDirect peers
- BrightInsight: BrightInsight operates a regulated digital health platform purpose-built for pharma and biopharma, offering SaMD, companion apps, and connected device solutions. It is the closest direct peer to Voluntis in terms of regulated platform positioning and pharma/biotech GTM motion.
- S3 Connected Health: S3 Connected Health provides regulated digital health platforms and connected drug-delivery companion apps for global pharma. It directly competes with Voluntis in the pharma digital companion and connected-device integration space.
- Biofourmis: Biofourmis builds digital therapeutics and AI-enabled remote monitoring platforms that integrate with pharma drug programs. It is a direct peer in the regulated SaMD and pharma partnership category.
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics in partnership with major pharma sponsors (e.g., Otsuka). It is a direct peer in the prescription DTx and pharma co-development model.
- Propeller Health: Propeller Health (now part of ResMed) offers connected inhaler sensors and companion apps for respiratory therapy, mirroring Voluntis's HeroTracker Sense and respiratory therapeutic area focus.
- mySugr: mySugr (acquired by Roche) provides a chronic disease companion app ecosystem integrated with pharma and device partners. It is comparable in patient-facing companion app model and pharma partnership monetization.
- Medisafe: Medisafe offers a medication adherence companion platform with pharma integrations. It directly competes with Voluntis in the medication adherence and patient engagement category.
- WellDoc: WellDoc develops FDA-cleared digital therapeutics, notably for diabetes, in partnership with pharma and payers. It is a direct peer in the regulated SaMD/DTx and pharma partnership model.
- AdhereTech: AdhereTech builds connected medication adherence devices and supporting software for pharma. It is a direct peer in connected drug-delivery devices with pharma partnerships.
- Huma: Huma (formerly Huma Therapeutics) operates a regulated digital health platform for hospitals, pharma, and research, including companion apps and SaMD modules. It is comparable as a regulated digital health platform with pharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Voluntis social profiles
Digital presenceVoluntis compliance and trust
Trust signalCompliance5 records
Voluntis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Voluntis leadership team
Management profileNumber of profiles
Profiles11 records
Voluntis funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Voluntis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Voluntis
What does Voluntis do?
Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.
Is Voluntis a public or private company?
Voluntis is a private company. It is classified as corporate owned and is currently operating.
When was Voluntis founded?
Voluntis was founded in 2001. It employs 51 to 100 people.
Where is Voluntis based?
Voluntis is headquartered in Suresnes, France, in the Europe region.
How does Voluntis make money?
Four revenue lines are on record. B2B Enterprise SaaS for Pharma is the primary driver. The others are connected Drug-Delivery Device Sales, licensing Agreements and study & Data / Real-World Evidence Services.
Who are Voluntis's main competitors?
Direct peers on record are BrightInsight, S3 Connected Health, Biofourmis, Click Therapeutics, Propeller Health, mySugr, Medisafe, WellDoc, AdhereTech and Huma.
Does Voluntis have an API?
No public API is recorded for Voluntis.
What industry is Voluntis in?
Voluntis's product category is Digital Health Software. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACAPAH, Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers). Its NAICS code is 51321 and its SIC code is 7372.